Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 26, 2017
Pharmacy Choice - Pharmaceutical News - BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia - June 26, 2017

Pharmacy News Article

 3/17/17 - BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia

By a News Reporter-Staff News Editor at Drug Week The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen's Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development phases, including pre-clinical/clinical studies and registration. The new biosimilar will be available for Russian patients already in 2017 (see also BIOCAD).

Today BIOCAD's interferon beta-1a biosimilar is the only registered biosimilar of Rebif in Russia and worldwide, which was developed in accordance with European Medicine Agency (EMA) guidelines. It showed no statistically meaningful difference in pharmacokinetics (PK) and pharmacodynamics (PD) parameters during phase I study and proved safety and efficacy equivalence to reference medicine in phase III study.

Included in the federal list of essential drugs and special reimbursement program for medicines used in rare debilitating diseases, interferon beta-1a is one of the most demanded therapeutic proteins the Russian government reimburses.

Roman Ivanov, the R&D vice-president of BIOCAD, said, Interferon beta-1a biosimilar is the third authorized BIOCAD's medicine for treatment of RRMS, which makes our biotechnological company the only manufacturer of both active pharmaceutical ingredients and drug products for all first generation disease-modifying therapies (DMTs). Moreover, 5 other drugs for use in MS, including 2 novel molecules, are in different development phases, supplementing the BIOCAD's autoimmune diseases pipeline View source version on businesswire.com: http://www.businesswire.com/news/home/20170303005253/en/

Keywords for this news article include: Antivirals, BIOCAD, Cytokines, Interferon-beta, Immunomodulatory, Interferon Type I, Biological Factors, Immunologic Agents, Interferon Beta-1a, Drugs and Therapies, Intercellular Signaling Peptides and Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Last Chance
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 02: HIV Medications: Newer Drugs, Newer Guidelines
Jul 03: Management of Major Depressive Disorders
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415